Description: Despite effective primary prophylaxis, HBV remains a substantial health problem both internationally and in Cambodia where neonatal transmission, unfortunately, still occurs. WHO recommends immediate administration of Hepatitis B vaccine and immunoglobulin in newborns to HBsAg+ mothers. Reported failure rates range from 1–14%, despite serovaccination. Factors associated with failure include HBeAg positivity and high HBV DNA VLs in the mother. Antiviral agents can be utilized to further decrease the risk of vertical transmission, especially in areas where WHO-recommended serovaccination are financially or operationally inaccessible. Several antiviral agents are currently presently used for this purpose.
Acronyme: TA PROHM
Goal: This project aims to implement PMTCT by reducing the HBV viral load in mothers by antivirals, typically initiated starting week 24 of pregnancy.